Stocks · News reference

Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa

Sep 30, 2026, 8:07 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 12:53 PMBenzinga Insights
Corvus Pharma Q2 2026 Earnings Call Transcript
Corvus Pharma (NASDAQ:CRVS) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
CRVS
BenzingaAug 27, 2026, 11:32 AMBenzinga Newsdesk
Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months
CRVS
BenzingaAug 6, 2026, 8:14 PMBenzinga Newsdesk
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) Estimate
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 90 percent decrease over losses of $(0.10) per share from the
CRVS